Systematic review of 49 studies (mostly case reports and series) of non-anti-TNF advanced therapies in pregnancy for immune-mediated inflammatory diseases: pooled rates were 0.55% major malformations and 8.16% miscarriage, with no differences vs anti-TNFs; evidence very low.
Meta-analysisn = 49 studies
Pingeon et al. Safety of advanced therapies during pregnancy in women with immune-mediated inflammatory diseases: a systematic review and meta-analysis